Learn how to quantify and manage risk at project, program, and portfolio levels. Assess the extent to which multiple indications and/or lines of therapy affect program risk and valuation. Quantify the likelihood that your R&D pipeline portfolio and commercial portfolio will meet annual corporate targets
Dr. Richard Bayney is President of Project & Portfolio Value Creation (PPVC), a consulting boutique that he founded in 2008 which provides training and education in Project, Program, Portfolio, Resource, and Risk Management as well as Business, Strategic, Portfolio, and Scenario Planning services. He is an adjunct faculty member at the University of Pennsylvania.
Dr. Bayney is a 23-year veteran of the Pharmaceutical & Biotechnology industry at Merck & Co., Bayer Corp. and AG, Bristol-Myers Squibb, and Johnson & Johnson Pharmaceutical Research & Development. In his previous position at Johnson & Johnson, Richard was Vice President, Portfolio Management & Decision Analysis. Dr. Bayney obtained his M.Sc. and Ph.D. from the University of London, MBA from Columbia University, and PMP from the Project Management Institute.
get the latest updates